经尿道等离子体电切术治疗前列腺增生131例

    Transurethral plasmakinetic resection of prostate for treatment of benign prostate hyperplasia: report of 131 cases

    • 摘要: 目的:评价经尿道等离子体电切术(transurethral plasmakinetic resection of prostate,TUPKVP)治疗良性前列腺增生(benign prostate hyperplasia,BPH)的有效性及安全性。方法:对131例TUPKVP治疗BPH患者的临床资料进行回顾性分析。结果:131例患者术中出血少,无前列腺电切综合征发生,术后3~6个月,经B超测量膀胱平均剩余尿量由术前120 ml降至14 ml。平均最大尿流率由术前8.5 ml/s降至21.5 ml/s。国际前列腺症状评分术前平均23分,术后平均5.5分;生活质量评分由术前平均5.1分降至术后1.6分,均有明显改善(P<0.01),无永久性尿失禁发生。结论:TUPKVP治疗BPH具有安全性高、并发症少、疗效好的优点,值得临床推广应用。

       

      Abstract: Objective: To assess the efficacy and safety of transurethral plasmakinetic resection of prostate(TUPKVP) for treatment of prostate hyperplasia.Methods: The clinical data of one hundred and thirty-one cases of symptomatic BPH treated by TUPKVP were analyzed retrospectively.Results: No severe hemorrhage or syndromes concerning the surgical procedure was observed.All the patients were followed up for 3 to 6 months.The average residual urine volume decreased from 120 ml to 14 ml;the average masimum flow rate increased from 8.5 ml/s to 21.5 ml/s;the average international prostate symptom score decreased from 23 to 5.5;and the average quality of life decreased from 5.1 to 1.6(P<0.01).No one developed permanent urinary incontinence.Conclusions: It suggests that TUPKVP has the advantages of high efficacy,high safety and less complication.It is worth popularizing.

       

    /

    返回文章
    返回